BIPOLAR DISORDERS, published by Wiley, is a leading international journal dedicated to advancing the understanding and treatment of bipolar disorders. Since its establishment in 1999, the journal has become a vital resource in the fields of Biological Psychiatry and Psychiatry and Mental Health, currently ranked in the Q2 category for Biological Psychiatry and Q1 for Psychiatry and Mental Health as of 2023. With impressive Scopus rankings, it stands at 75th out of 567 in Psychiatry and Mental Health and 11th out of 51 in Biological Psychiatry, reflecting its influential role in shaping mental health research. The journal not only focuses on empirical studies, reviews, and clinical reports but also encourages innovative methodological advancements in understanding bipolar disorders. Although it does not offer Open Access, its extensive coverage from 1999 to 2024 ensures that practitioners, researchers, and students have access to a wealth of knowledge critical for the development of effective therapeutic interventions. For those engaging with cutting-edge research in psychiatric care, BIPOLAR DISORDERS serves as an essential platform for knowledge dissemination and academic discourse.

The Journal of the Korean Academy of Child and Adolescent Psychiatry (ISSN: 1225-729X; E-ISSN: 2233-9183) stands as a pivotal resource in the fields of child and adolescent mental health, contributing significantly to the dialogue on psychiatric practices and research in South Korea and beyond. Published by the KOREAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY, this journal is recognized for its dedication to advancing the understanding of psychiatric disorders that affect children and adolescents, as evidenced by its Q3 ranking in both Pediatrics, Perinatology and Child Health and Psychiatry and Mental Health categories for 2023. Operated from Seoul, South Korea, the journal facilitates knowledge-sharing among researchers and practitioners, providing insights into clinical practices and innovative treatment methodologies. Although not openly accessible, the journal emphasizes quality over quantity in its selection of studies, making each article a valuable contribution to the field. As the journal continues to publish impactful research through 2024, it remains essential reading for those committed to the well-being of younger populations and their families.

PSYCHIATRY RESEARCH is a leading journal published by Elsevier Ireland Ltd, dedicated to advancing the field of psychiatry and mental health through the dissemination of rigorous research. With an impressive impact factor and categorized in the top quartile (Q1) of both Biological Psychiatry and Psychiatry and Mental Health in 2023, this journal ranks 14th in the field of Medicine _ Psychiatry and Mental Health out of 567 journals, and 4th in Neuroscience _ Biological Psychiatry out of 51, showcasing its influence and quality. Since its inception in 1979, PSYCHIATRY RESEARCH has provided a platform for innovative studies, clinical trials, and comprehensive reviews aimed at understanding the complexities of mental health disorders. Although it operates under a traditional access model, the journal remains committed to making vital research available to the academic community, ensuring that both seasoned professionals and budding researchers have access to groundbreaking findings. Positioned as a hub for psychiatric research, it caters to a diverse audience including clinicians, psychologists, and students, empowering them to contribute to the evolving landscape of mental health care.

Alpha Psychiatry, published by AVES, stands at the forefront of mental health research and psychiatric advancements. With a commitment to disseminating high-quality and impactful studies, this journal serves as a critical platform for scholars, clinicians, and students interested in exploring the complexities of psychiatric disorders and treatment methodologies. Although the impact factor and specific scope details are still evolving, Alpha Psychiatry is dedicated to fostering interdisciplinary dialogue and promoting innovative research that tackles contemporary challenges in the field of psychiatry. As an open-access journal, it ensures that research is widely accessible, enhancing knowledge transfer and collaboration within the global scientific community. Located in Istanbul, Turkiye, the journal proudly represents a rich academic tradition, aiming to contribute significantly to the global discourse on mental health.

Neuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.

ACTAS ESPANOLAS DE PSIQUIATRIA, published by the renowned JUAN JOSE LOPEZ-IBOR FOUNDATION, serves as a vital resource in the field of psychiatry and mental health, particularly within the Spanish-speaking academic community. With its ISSN 1139-9287 and E-ISSN 1578-2735, this journal has been a critical platform for disseminating high-quality research since its inception in 1996 and continues to contribute valuable insights until 2024. As a recognized journal in the Q3 category of psychiatry and mental health, it ranks 387 out of 567 in Scopus, placing it within the 31st percentile, thereby indicating a growing influence among its peers. The journal’s open access options enhance its accessibility, encouraging a broader readership to engage with contemporary research issues in mental health. Researchers, professionals, and students alike will find ACTAS ESPANOLAS DE PSIQUIATRIA essential for staying informed on the latest developments and innovations in psychiatric practice and research.

BRAIN & DEVELOPMENT is a prestigious academic journal published by ELSEVIER, renowned for its pivotal contributions to the fields of developmental neuroscience, neurology, and pediatrics. Established in 1979, this journal has become an essential resource for researchers and clinicians alike, as it explores the complexities of brain development and associated neurological disorders in children. With an impactful focus on advancing scientific understanding, BRAIN & DEVELOPMENT is currently ranked in the Q3 quartile in Developmental Neuroscience and Clinical Neurology and Q2 in Pediatrics, reflecting its significance within the medical community. Its ISSN 0387-7604 and E-ISSN 1872-7131 underline its established presence in academic literature. While the journal does not offer open access options, it continues to be a key platform for disseminating new research findings and fostering innovation in the understanding of pediatric neurological health. The journal's commitment to quality research is further evidenced by its ongoing publication trajectory up until 2024, making it a vital source of knowledge for students, professionals, and educators in related fields.

EUROPEAN NEUROPSYCHOPHARMACOLOGY, published by Elsevier, is a prestigious academic journal that serves as a cornerstone in the field of neuropsychopharmacology, embracing multidisciplinary research at the intersection of neuroscience, psychiatry, and pharmacology. Since its establishment in 1990, this journal has consistently delivered cutting-edge research and reviews that drive forward our understanding of central nervous system disorders and their treatment. With an impressive impact factor and ranked in the Q1 category for several disciplines, including Biological Psychiatry and Neurology, it attracts submissions from leading researchers globally. The journal’s Scopus rankings reflect its significant influence, ranking in the top echelons across various categories such as Medicine and Neuroscience. While the journal maintains subscription access, readers are encouraged to explore the breadth of important findings that contribute to advancements in treatment options and improve patient care. EUROPEAN NEUROPSYCHOPHARMACOLOGY not only supports the dissemination of pivotal research but also fosters collaboration and dialogue within the scientific community, making it an essential resource for researchers, clinicians, and students dedicated to the complexities of brain health.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE is a distinguished publication in the field of Psychiatry and Mental Health, published by TAYLOR & FRANCIS LTD in the United Kingdom. With an impressive 2023 impact factor that places it in the Q2 category among its peers, this journal is an essential resource for researchers, clinicians, and students dedicated to advancing mental health practices and understanding psychiatric disorders. Covering topics from clinical studies to innovative treatment methodologies, the journal welcomes original research, reviews, and case studies that contribute valuable insights into clinical practice. Accessible without any open access restrictions, the journal has been a pivotal platform since its inception in 1997, facilitating knowledge exchange in the field up to 2024. As evidenced by its notable Scopus ranking within the top 73rd percentile of Psychiatry and Mental Health, it remains committed to impacting clinical practices significantly.

MOLECULAR PSYCHIATRY, published by SpringerNature, is a premier peer-reviewed journal that has established itself as a leading platform for the dissemination of cutting-edge research in the fields of neuroscience, molecular biology, and psychiatry. With an impressive impact factor and a reputation for excellence, the journal is ranked Q1 in key categories, signifying its high academic quality and relevance. The journal’s scope spans groundbreaking studies and innovative therapeutic approaches that intersect at the molecular and cellular levels, providing invaluable insights into the biological underpinnings of psychiatric disorders. Since its inception in 1996, MOLECULAR PSYCHIATRY has evolved to support both established and emerging researchers, fostering a collaborative environment that enhances the understanding of mental health. It is committed to improving access to scientific knowledge, although it currently does not offer open access options. With its headquarters in London, the journal continues to play a pivotal role in enhancing the global dialogue on psychiatric and neurological advancements, making it an essential resource for academics and professionals dedicated to advancing mental health sciences.